Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Positron emission tomography and bone metastases.

Ignac Fogelman1, Gary Cook, Ora Israel

  • 1Division of Imaging, King's College, London, United Kingdom. ignac.fogelman@kcl.ac.uk

Seminars in Nuclear Medicine
|March 15, 2005
PubMed
Summary

2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) shows promise for detecting bone metastases, but its effectiveness varies by cancer type and lesion characteristics. Further research is needed to clarify its clinical relevance, especially when FDG-PET scans are negative.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Hemopericardium Due to Atrioventricular Disruption After Mitral Valve Replacement With Nonemergent Left Ventricular Pseudoaneurysm Repair.

Annals of thoracic surgery short reports·2026
Same author

Incident learning systems to improve patient safety in nuclear medicine across Europe: results of the MARLIN study.

European journal of nuclear medicine and molecular imaging·2026
Same author

A Randomized, Phase II Clinical Trial of FLT-PET and FDG-PET for Early Response Assessment of Neoadjuvant Systemic Therapy in Triple Negative Breast Cancer.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same author

Imaging trends in diabetic foot infections.

Seminars in nuclear medicine·2026
Same author

The role of multimodality imaging in selection, response assessment, and follow-up of patients receiving <sup>177</sup>Lutetium-PSMA-therapy.

Insights into imaging·2026
Same author

Successful Replication of the Transconal Repair Technique for Anomalous Aortic Origin of the Left Main Coronary Artery.

JACC. Case reports·2025

Area of Science:

  • Oncology
  • Nuclear Medicine
  • Radiology

Background:

  • The use of 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) is increasing for cancer evaluation.
  • Its specific role in identifying bone metastases remains unclear, with varying performance across different cancer types.
  • FDG uptake in bone metastases is assumed to be directly into tumor cells.

Purpose of the Study:

  • To evaluate the role and limitations of FDG-PET in the detection of bone metastases.
  • To compare FDG-PET performance against conventional imaging methods like bone scans and CT.
  • To explore factors influencing FDG-PET accuracy, including tumor type, morphology, location, and prior treatment.

Main Methods:

  • Review of existing literature comparing FDG-PET with conventional imaging for bone metastases.

Related Experiment Videos

  • Analysis of factors affecting FDG-PET sensitivity and specificity, such as cancer histology and lesion characteristics.
  • Consideration of the impact of prior treatment on imaging findings.

    • Main Results:

    • FDG-PET sensitivity and specificity vary significantly by cancer type (e.g., breast, lung, prostate, lymphoma, myeloma).
    • For breast and lung cancer, FDG-PET may have similar sensitivity but lower specificity than bone scans.
    • FDG-PET is less sensitive than bone scans for prostate cancer but shows significant value in myeloma detection.
    • Lesion morphology (sclerotic, lytic, mixed) and location influence FDG uptake patterns.
    • Previous treatment can lead to incongruent imaging findings (CT-positive/PET-negative lesions).

    Conclusions:

    • FDG-PET is a valuable tool for detecting bone metastases in certain cancers like myeloma.
    • Its utility in other cancers, such as breast and prostate, requires careful consideration due to variable sensitivity and specificity.
    • The clinical significance of negative FDG-PET findings in the presence of other imaging evidence needs further investigation.